Today: 1 May 2026
Charles Schwab stock rises after earnings; Fed decision and crypto plans come next

Charles Schwab stock rises after earnings; Fed decision and crypto plans come next

New York, Jan 21, 2026, 15:05 ET — Regular Session

  • Schwab shares climbed roughly 1.5% following a fourth-quarter profit boost driven by higher interest income and increased trading activity
  • Net interest revenue surged over 25%, while quarterly core net new assets reached a record high
  • Schwab CEO Rick Wurster confirmed the company is still aiming to roll out spot Bitcoin and Ethereum trading during the first half of 2026

Shares of The Charles Schwab Corporation (SCHW) climbed Wednesday following a strong quarterly profit report, lifting trading-related stocks broadly. Schwab was up roughly 1.5% to $102.55 in afternoon action, after swinging between $97.10 and $104.78. Interactive Brokers jumped around 7.1%, and Robinhood added 1.2%. Both the SPDR S&P 500 ETF (SPY) and the Financial Select Sector SPDR Fund (XLF) also moved higher.

This print is crucial since Schwab straddles two key metrics investors watch closely: client cash and client clicks. More trades mean higher fees, while bigger cash balances boost the firm’s income from interest spreads.

Rates drive everything here. Schwab’s earnings hinge on where clients park their cash and the returns they pull, which get shakier as the market guesses the Fed’s next step.

Schwab reported a 19% rise in fourth-quarter net revenue to $6.34 billion, slightly missing analysts’ $6.37 billion target, according to LSEG data. Net income jumped to $2.46 billion, or $1.33 per share, up from $1.84 billion, or 94 cents, the previous year. Net interest revenue — the difference between earnings on assets and costs on liabilities — surged over 25% to $3.17 billion as clients adjusted portfolios amid uncertainty about the Fed’s rate moves and geopolitical tensions. Core net new assets, which measure client inflows minus withdrawals, set a new record at $163.9 billion.

Total client assets hit a record $11.90 trillion, up 18%, while client accounts climbed to 46.5 million. CEO Rick Wurster said Schwab had “delivered growth on all fronts.” Daily average trading volume surged 31% to 8.3 million, pushing trading revenue up 22%. Asset management and administration fees increased 15% to $1.7 billion, the company reported. Net interest margin expanded 57 basis points to 2.90%, and sweep cash balances closed December at $453.7 billion as bank supplemental funding dropped to $5.1 billion. Schwab repurchased 29.2 million shares for $2.7 billion. CFO Mike Verdeschi confirmed “capital ratios remained strong.” Charles Schwab Press Room

During the earnings call, Wurster told analysts Schwab is still “on track to launch spot trading on Bitcoin and Ethereum in the first half of this year,” aiming to expand its reach among active-trader clients and new product offerings. He also made it clear the firm has no plans to enter sports-related prediction markets. Investing.com

Net interest revenue reflects the spread Schwab earns on customer cash and securities it holds, usually climbing when rates rise or more cash remains in sweep accounts. Trading revenue depends on customer activity and can drop quickly if markets calm down.

That balance works both ways. Economists surveyed by Reuters this week forecast the Fed will hold its policy rate between 3.50% and 3.75% through March. Yet, if rates fall faster or clients flock again to higher-yield options, Schwab’s interest income could come under pressure.

The next major event is the Fed meeting on Jan. 27-28, with the rate decision and press conference set for Jan. 28. Traders are focused on the rate trajectory and Schwab’s first-quarter cash flow trends, searching for early signs of whether the recent earnings boost will hold.

Stock Market Today

  • Seaport Therapeutics Upsizes IPO to $255M, CEO Highlights New Biotech Pathway
    May 1, 2026, 2:02 PM EDT. Seaport Therapeutics raised $254.9 million in an upsized Nasdaq IPO, exceeding initial $180 million estimates. CEO Daphne Zohar highlighted a shift from traditional M&A (mergers and acquisitions) to public offerings, reflecting confidence in developing and marketing their depression drug pipeline independently. The company may raise an additional $38.2 million through underwriters' option. Zohar pointed to industry changes where biotech firms are now focusing on advancing medicines directly to patients, citing success stories like Karuna Therapeutics and Intra-Cellular Therapies. Seaport's board recently welcomed Sharon Mates, who led Intra-Cellular to a $1.5 billion drug launch before its J&J acquisition. This IPO signals renewals in the biotech public market despite recent Big Pharma dealmaking.

Latest article

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

1 May 2026
The Dow Jones Industrial Average fell 78.72 points to 49,573.42 by midday Friday, reversing an early rally as tariff concerns weighed on gains from Apple and other strong earnings reports. President Donald Trump announced a 25% tariff on EU-made cars and trucks starting next week. Apple reported quarterly revenue of $111.2 billion, up 17% year over year. Oil prices dropped after Iran sent a new negotiation proposal.
US Stock Market Today: Why the S&P 500 and Nasdaq Are Hitting Fresh Highs

US Stock Market Today: Why the S&P 500 and Nasdaq Are Hitting Fresh Highs

1 May 2026
The S&P 500 rose 0.48% and the Nasdaq 0.96% to record highs Friday, while the Dow slipped 0.11%. Apple shares climbed after reporting its strongest quarterly sales growth in over four years. Atlassian and other software stocks rallied on strong cloud demand. Exxon and Chevron beat profit estimates but cited pressure from Middle East conflict and volatile oil prices.
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

1 May 2026
Recursion Pharmaceuticals said founder and board chair Chris Gibson will not seek re-election at the June 17 annual meeting, months after stepping down as CEO. The company reports first-quarter results May 6, with investors watching for updates on cash, clinical progress, and its AI drug platform. Recursion last reported $753.9 million in cash and narrowed its quarterly net loss. Gibson will remain chair until his term ends.
Kenvue stock price slips as Kimberly-Clark drops, deal vote stays in focus
Previous Story

Kenvue stock price slips as Kimberly-Clark drops, deal vote stays in focus

Nvidia stock jumps 3% as China chip headlines and an export-bill fight keep NVDA in play
Next Story

Nvidia stock jumps 3% as China chip headlines and an export-bill fight keep NVDA in play

Go toTop